Abstract
Acute myeloid leukemia occurs naturally in the evolution of myelodysplastic syndrome (MDS), typically in MDS with excess blasts type 2. The risk of progression is around 33%. We present the case of an elderly patient who was diagnosed with MDS single dysplasia in 2016. He was treated with erythropoietin. In 2021, the disease evolved into MDS with excess blast type 2 and then in acute myeloid leukemia in a short period of time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
